Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19107154 | 0.86 | HRH4 (0.50) | ELANEHRH4CHIA | |
| SCHEMBL24809669 | 0.86 | IRAK4 (0.43) | ELANECHRM4CXCR4KMT2A | |
| SCHEMBL29945085 | 0.82 | ELANE (0.53) | ELANEKCNH2KDM4ERAD52L3MBTL1 | |
| SCHEMBL29904618 | 0.81 | KCNH2 (0.52) | ELANEKCNH2KDM4ERAD52L3MBTL1 | |
| SCHEMBL26790144 | 0.77 | CYP1A2 (0.45) | KDM4EKMT2A | |
| SCHEMBL10094245 | 0.77 | CYP1A2 (0.49) | KDM4EL3MBTL1KMT2A | |
| SCHEMBL2609324 | 0.75 | CYP1A2 (0.51) | KDM4EL3MBTL1KMT2A | |
| SCHEMBL11951657 | 0.75 | PDE10A (0.42) | KMT2A | |
| SCHEMBL10094290 | 0.75 | PDE10A (0.42) | KMT2A | |
| SCHEMBL10094284 | 0.75 | PDE10A (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | ELANE 927/4885KCNH2 1689/4885KDM4E 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.